Gastroenteropancreatic neuroendocrine tumour disease
Not recruitingStudy of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Disease:Gastroenteropancreatic neuroendocrine tumour disease
- Substances:Calcium FolinateCapecitabine+8
Spain- Participants:18–64 years · 65+ years
- Substances:Calcium Folinate
- Sponsor:ITM Solucin GmbH







